{"id":1006983,"date":"2026-09-30T07:48:03","date_gmt":"2026-09-30T11:48:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/immunome-announces-ind-clearance-for-im-1340-a-potential-first-in-class-antibody-drug-conjugate-for-the-treatment-of-solid-tumors\/"},"modified":"2026-09-30T07:48:03","modified_gmt":"2026-09-30T11:48:03","slug":"immunome-announces-ind-clearance-for-im-1340-a-potential-first-in-class-antibody-drug-conjugate-for-the-treatment-of-solid-tumors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/immunome-announces-ind-clearance-for-im-1340-a-potential-first-in-class-antibody-drug-conjugate-for-the-treatment-of-solid-tumors\/","title":{"rendered":"Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position:inside }\n.bwlistdisc { list-style-type: disc }\n.bwalignl { text-align: left }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>IM-1340 incorporates Immunome&#8217;s proprietary HC74 topoisomerase I inhibitor payload and targets a transport receptor expressed across solid tumors, including neuroendocrine tumors, lung cancer, and colorectal cancer<\/li>\n<li>Company expects to initiate Phase 1 first-in-human study in patients with advanced solid tumors in the fourth quarter of 2026<\/li>\n<li>IM-1340 is Immunome\u2019s fifth program in clinical development<\/li>\n<\/ul>\n<p class=\"bwalignl\">BOTHELL, Wash.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fimmunome.com%2F&amp;esheet=54613345&amp;newsitemid=20260930301168&amp;lan=en-US&amp;anchor=Immunome%2C+Inc.&amp;index=1&amp;md5=244e0b58c36208459cfe2aa3b7e817ec\">Immunome, Inc.<\/a> (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for IM-1340, a potential first-in-class antibody-drug conjugate (ADC) for the treatment of advanced solid tumors.<\/p>\n<p>IM-1340 is designed to target a transport receptor with a unique tumor expression profile spanning solid tumors, including neuroendocrine tumors, lung cancer, and colorectal cancer. It incorporates HC74, Immunome&#8217;s proprietary topoisomerase I (TOP1) inhibitor payload. Preclinical studies demonstrated encouraging anti-tumor activity across multiple tumor models, supporting the decision to advance this program into clinical development.<\/p>\n<p>\u201cIND clearance for IM-1340 marks another milestone in the advancement of Immunome&#8217;s ADC platform and demonstrates our ability to rapidly progress novel HC74-based programs into the clinic,\u201d said Clay Siegall, Ph.D., President and Chief Executive Officer of Immunome. \u201cWe believe IM-1340 has the potential to treat multiple solid tumor types by combining a differentiated target with the favorable properties of our proprietary HC74 payload. We look forward to initiating clinical evaluation of IM-1340 and continuing to expand our ADC pipeline.\u201d<\/p>\n<p>The Phase 1 study, which Immunome expects to initiate in the fourth quarter of 2026, is an open-label, multicenter dose-escalation and expansion trial designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of IM-1340 in patients with advanced solid tumors.<\/p>\n<p><b>About IM-1340<\/b><\/p>\n<p>IM-1340 is a potential first-in-class ADC incorporating Immunome&#8217;s proprietary HC74 topoisomerase I inhibitor payload. The investigational therapy targets a transport receptor with expression across solid tumors, including neuroendocrine tumors, lung cancer, and colorectal cancer. In preclinical studies, IM-1340 demonstrated anti-tumor activity, including tumor regressions following a single dose in multiple in vivo models.<\/p>\n<p><b>About Immunome, Inc.<\/b><\/p>\n<p>Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies. We are advancing an innovative portfolio of therapeutics, supported by a leadership team with deep experience in the design, development, and commercialization of cutting-edge therapies, including antibody-drug conjugates. Our pipeline includes varegacestat, an investigational gamma secretase inhibitor for which an NDA has been accepted by the U.S. FDA; IM-1021, a clinical-stage ROR1 ADC; IM-1617, a clinical-stage solid tumor ADC; IM-3050, a clinical-stage FAP-targeted radiotherapy; and IM-1340, an IND-cleared solid tumor ADC. We are also advancing a broad portfolio of early-stage ADCs pursuing undisclosed solid tumor targets. For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fimmunome.com%2F&amp;esheet=54613345&amp;newsitemid=20260930301168&amp;lan=en-US&amp;anchor=www.immunome.com&amp;index=2&amp;md5=60c02d3d0b0de97ff40532611fdc87c5\">www.immunome.com<\/a>.<\/p>\n<p><b>Cautionary Statement Regarding Forward-Looking Statements<\/b><\/p>\n<p>Statements in this press release that are not purely historical in nature are \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995. We use words such as \u201cpotential,\u201d \u201cbelieve,\u201d \u201cexpect,\u201d \u201cexpects,\u201d \u201cdesigned to,\u201d \u201clook forward to,\u201d and similar expressions to identify these forward-looking statements. These forward-looking statements include statements regarding: the advancement, development, clinical evaluation and therapeutic benefits of IM-1340, including its potential to treat multiple solid tumor types; Immunome\u2019s expected timing for initiation of a Phase 1 clinical trial of IM-1340; the potential of Immunome\u2019s ADC platform and proprietary HC74 payload; the continued expansion of Immunome\u2019s ADC pipeline; the potential of Immunome\u2019s targeted oncology therapies to be first-in-class or best-in-class therapies; and other statements regarding management\u2019s intentions, plans, beliefs, expectations and forecasts for the future. These forward-looking statements are based on Immunome\u2019s current expectations and involve assumptions that may never materialize or may prove to be incorrect; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including the risk that clinical development of IM-1340 or other product candidates may be delayed or unsuccessful; the risk that preclinical results may not be predictive of clinical performance or that initial clinical results may not be indicative of subsequent results; the risk that regulatory approvals for Immunome\u2019s product candidates are not obtained, are delayed or are subject to unanticipated conditions; the risk that the timing, conduct, enrollment or results of clinical trials may differ from current expectations; the risk that Immunome will not be able to realize the benefits of its strategic transactions; Immunome\u2019s ability to advance and expand its ADC pipeline; and other risks and uncertainties included under the caption \u201cRisk Factors\u201d in Immunome\u2019s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the Securities and Exchange Commission on August 11, 2026. These documents can also be accessed on Immunome\u2019s website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.immunome.com&amp;esheet=54613345&amp;newsitemid=20260930301168&amp;lan=en-US&amp;anchor=www.immunome.com&amp;index=3&amp;md5=d402fba0f08c77bffc9476d5e71bd570\">www.immunome.com<\/a> by clicking on the link \u201cFinancials\u201d under the \u201cInvestors\u201d tab. The forward-looking statements included in this press release are made only as of the date hereof. Except as required by law, Immunome assumes no obligation and does not intend to update any forward-looking statements included in this press release.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260930301168r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260930301168\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260930301168\/en\/<\/a><\/span><\/p>\n<p class=\"bwalignl\">Investor Contact:<br \/>Max Rosett<br \/>Chief Financial Officer, Immunome<br \/><a rel=\"nofollow\" href=\"mailto:investors@immunome.com\">investors@immunome.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America Washington<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Oncology FDA Health Clinical Trials Pharmaceutical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260930301168\/en\/2917586\/3\/Immunome_Logo_Registered_RGB.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors IM-1340 incorporates Immunome&#8217;s proprietary HC74 topoisomerase I inhibitor payload and targets a transport receptor expressed across solid tumors, including neuroendocrine tumors, lung cancer, and colorectal cancer Company expects to initiate Phase 1 first-in-human study in patients with advanced solid tumors in the fourth quarter of 2026 IM-1340 is Immunome\u2019s fifth program in clinical development BOTHELL, Wash.&#8211;(BUSINESS WIRE)&#8211;Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for IM-1340, a potential first-in-class antibody-drug conjugate (ADC) for the treatment &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunome-announces-ind-clearance-for-im-1340-a-potential-first-in-class-antibody-drug-conjugate-for-the-treatment-of-solid-tumors\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1006983","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunome-announces-ind-clearance-for-im-1340-a-potential-first-in-class-antibody-drug-conjugate-for-the-treatment-of-solid-tumors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors IM-1340 incorporates Immunome&#8217;s proprietary HC74 topoisomerase I inhibitor payload and targets a transport receptor expressed across solid tumors, including neuroendocrine tumors, lung cancer, and colorectal cancer Company expects to initiate Phase 1 first-in-human study in patients with advanced solid tumors in the fourth quarter of 2026 IM-1340 is Immunome\u2019s fifth program in clinical development BOTHELL, Wash.&#8211;(BUSINESS WIRE)&#8211;Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for IM-1340, a potential first-in-class antibody-drug conjugate (ADC) for the treatment &hellip; Continue reading &quot;Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunome-announces-ind-clearance-for-im-1340-a-potential-first-in-class-antibody-drug-conjugate-for-the-treatment-of-solid-tumors\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-30T11:48:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260930301168r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunome-announces-ind-clearance-for-im-1340-a-potential-first-in-class-antibody-drug-conjugate-for-the-treatment-of-solid-tumors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunome-announces-ind-clearance-for-im-1340-a-potential-first-in-class-antibody-drug-conjugate-for-the-treatment-of-solid-tumors\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors\",\"datePublished\":\"2026-09-30T11:48:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunome-announces-ind-clearance-for-im-1340-a-potential-first-in-class-antibody-drug-conjugate-for-the-treatment-of-solid-tumors\\\/\"},\"wordCount\":916,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunome-announces-ind-clearance-for-im-1340-a-potential-first-in-class-antibody-drug-conjugate-for-the-treatment-of-solid-tumors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260930301168r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunome-announces-ind-clearance-for-im-1340-a-potential-first-in-class-antibody-drug-conjugate-for-the-treatment-of-solid-tumors\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunome-announces-ind-clearance-for-im-1340-a-potential-first-in-class-antibody-drug-conjugate-for-the-treatment-of-solid-tumors\\\/\",\"name\":\"Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunome-announces-ind-clearance-for-im-1340-a-potential-first-in-class-antibody-drug-conjugate-for-the-treatment-of-solid-tumors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunome-announces-ind-clearance-for-im-1340-a-potential-first-in-class-antibody-drug-conjugate-for-the-treatment-of-solid-tumors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260930301168r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-09-30T11:48:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunome-announces-ind-clearance-for-im-1340-a-potential-first-in-class-antibody-drug-conjugate-for-the-treatment-of-solid-tumors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunome-announces-ind-clearance-for-im-1340-a-potential-first-in-class-antibody-drug-conjugate-for-the-treatment-of-solid-tumors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunome-announces-ind-clearance-for-im-1340-a-potential-first-in-class-antibody-drug-conjugate-for-the-treatment-of-solid-tumors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260930301168r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260930301168r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunome-announces-ind-clearance-for-im-1340-a-potential-first-in-class-antibody-drug-conjugate-for-the-treatment-of-solid-tumors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/immunome-announces-ind-clearance-for-im-1340-a-potential-first-in-class-antibody-drug-conjugate-for-the-treatment-of-solid-tumors\/","og_locale":"en_US","og_type":"article","og_title":"Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors - Market Newsdesk","og_description":"Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors IM-1340 incorporates Immunome&#8217;s proprietary HC74 topoisomerase I inhibitor payload and targets a transport receptor expressed across solid tumors, including neuroendocrine tumors, lung cancer, and colorectal cancer Company expects to initiate Phase 1 first-in-human study in patients with advanced solid tumors in the fourth quarter of 2026 IM-1340 is Immunome\u2019s fifth program in clinical development BOTHELL, Wash.&#8211;(BUSINESS WIRE)&#8211;Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for IM-1340, a potential first-in-class antibody-drug conjugate (ADC) for the treatment &hellip; Continue reading \"Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/immunome-announces-ind-clearance-for-im-1340-a-potential-first-in-class-antibody-drug-conjugate-for-the-treatment-of-solid-tumors\/","og_site_name":"Market Newsdesk","article_published_time":"2026-09-30T11:48:03+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260930301168r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunome-announces-ind-clearance-for-im-1340-a-potential-first-in-class-antibody-drug-conjugate-for-the-treatment-of-solid-tumors\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunome-announces-ind-clearance-for-im-1340-a-potential-first-in-class-antibody-drug-conjugate-for-the-treatment-of-solid-tumors\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors","datePublished":"2026-09-30T11:48:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunome-announces-ind-clearance-for-im-1340-a-potential-first-in-class-antibody-drug-conjugate-for-the-treatment-of-solid-tumors\/"},"wordCount":916,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunome-announces-ind-clearance-for-im-1340-a-potential-first-in-class-antibody-drug-conjugate-for-the-treatment-of-solid-tumors\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260930301168r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunome-announces-ind-clearance-for-im-1340-a-potential-first-in-class-antibody-drug-conjugate-for-the-treatment-of-solid-tumors\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/immunome-announces-ind-clearance-for-im-1340-a-potential-first-in-class-antibody-drug-conjugate-for-the-treatment-of-solid-tumors\/","name":"Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunome-announces-ind-clearance-for-im-1340-a-potential-first-in-class-antibody-drug-conjugate-for-the-treatment-of-solid-tumors\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunome-announces-ind-clearance-for-im-1340-a-potential-first-in-class-antibody-drug-conjugate-for-the-treatment-of-solid-tumors\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260930301168r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-09-30T11:48:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunome-announces-ind-clearance-for-im-1340-a-potential-first-in-class-antibody-drug-conjugate-for-the-treatment-of-solid-tumors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/immunome-announces-ind-clearance-for-im-1340-a-potential-first-in-class-antibody-drug-conjugate-for-the-treatment-of-solid-tumors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunome-announces-ind-clearance-for-im-1340-a-potential-first-in-class-antibody-drug-conjugate-for-the-treatment-of-solid-tumors\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260930301168r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260930301168r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunome-announces-ind-clearance-for-im-1340-a-potential-first-in-class-antibody-drug-conjugate-for-the-treatment-of-solid-tumors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1006983","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1006983"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1006983\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1006983"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1006983"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1006983"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}